CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.5% - Time to Sell?

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) fell 0.5% during trading on Monday . The company traded as low as $43.25 and last traded at $43.70. 525,122 shares were traded during trading, a decline of 77% from the average session volume of 2,299,289 shares. The stock had previously closed at $43.92.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on CRSP. TD Cowen upgraded shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price target on the stock in a research note on Wednesday, February 12th. Royal Bank of Canada dropped their price target on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating on the stock in a research note on Wednesday, February 12th. Morgan Stanley upped their price target on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the company an "underweight" rating in a research note on Friday, February 14th. Chardan Capital dropped their price target on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Finally, JMP Securities restated a "market outperform" rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $73.11.

Remove Ads

CRISPR Therapeutics Trading Up 5.1 %

The company's fifty day moving average is $42.79 and its 200 day moving average is $45.79. The company has a market cap of $3.91 billion, a P/E ratio of -10.42 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Activity at CRISPR Therapeutics

In related news, Director John Greene bought 7,000 shares of the company's stock in a transaction dated Wednesday, February 26th. The stock was purchased at an average cost of $44.85 per share, with a total value of $313,950.00. Following the transaction, the director now owns 7,000 shares in the company, valued at approximately $313,950. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 18,360 shares of the firm's stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now directly owns 171,613 shares of the company's stock, valued at approximately $9,473,037.60. This represents a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.10% of the stock is owned by insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Wood Tarver Financial Group LLC purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter worth about $30,000. Ameriflex Group Inc. purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter worth about $36,000. GF Fund Management CO. LTD. purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter worth about $71,000. Sunbelt Securities Inc. lifted its position in shares of CRISPR Therapeutics by 108.6% in the 4th quarter. Sunbelt Securities Inc. now owns 6,165 shares of the company's stock worth $238,000 after purchasing an additional 3,210 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of CRISPR Therapeutics by 2.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 690,191 shares of the company's stock worth $27,166,000 after purchasing an additional 13,865 shares during the period. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.